BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines Ltd. - American Depositary Shares (ONC)
Company Research
Source: Business Wire
BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLLFirst results from Phase 1/2 sonrotoclax monotherapy study will demonstrate notable speed and depth of clinical responses in patients with R/R MCL, a rare, aggressive cancerNew efficacy and safety data will highlight the benefits of potential first-in-class BTK degrader BGB-16673 in patients across multiple hematological malignancies SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the company’s
Show less
Read more
Impact Snapshot
Event Time:
ONC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONC alerts
High impacting BeOne Medicines Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ONC
News
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- BeOne Medicines (NASDAQ:ONC) was upgraded by analysts at Sanford C. Bernstein to an "outperform" rating.MarketBeat
- BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEABusiness Wire
- BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
ONC
Earnings
- 11/6/25 - Beat
ONC
Sec Filings
- 1/9/26 - Form 4
- 1/5/26 - Form 4
- 12/17/25 - Form 4
- ONC's page on the SEC website